文献速递免疫规划传染病防控与疫情报告

撒哈拉以南非洲随机试验中HIV感染婴儿和儿童接种RTS,S/AS01疟疾疫苗的安全性和免疫原性

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
PubMed 文献 · Vaccine · 2019-11-07

在撒哈拉以南非洲七国开展的III期随机对照试验中,对HIV感染婴儿和儿童接种RTS,S/AS01疟疾疫苗的安全性及免疫原性进行评估,结果显示HIV感染儿童中疫苗安全性特征与对照疫苗(脑膜炎球菌或狂犬病疫苗)相当,具有免疫原性但抗体浓度低于HIV状态未知或阴性儿童。

要点

  • HIV感染儿童中RTS,S/AS01安全性特征与对照疫苗(脑膜炎球菌或狂犬病疫苗)相当。
  • RTS,S/AS01在HIV感染儿童中具有免疫原性,但抗体浓度低于HIV状态未知或阴性儿童。
  • 接种后1个月抗环子孢子抗体几何平均浓度:HIV感染儿童193.3 EU/mL vs 免疫原性对照491.5 EU/mL(p=0.0001)。

核心结论

  • HIV感染儿童中RTS,S/AS01的安全性特征与对照疫苗(脑膜炎球菌或狂犬病疫苗)相当。
  • RTS,S/AS01在HIV感染儿童中具有免疫原性,但抗体浓度低于HIV状态未知或阴性的儿童。

研究设计与样本

  • 在撒哈拉以南非洲七个国家开展的大型III期随机对照试验中,对经医学史或临床怀疑并PCR或抗体检测确认的HIV感染儿童亚组进行分析。
  • 婴儿(6-12周龄)和儿童(5-17月龄)随机接受4剂RTS,S/AS01(R3R组)、3剂RTS,S/AS01加1剂对照疫苗(R3C组)或4剂对照疫苗(C3C组),于研究第0、1、2和20月接种。
  • 排除WHO III/IV期HIV病婴儿和儿童,但未对所有参与者常规进行HIV检测。
  • 评估严重不良事件(SAEs)和抗环子孢子(CS)抗体。

主要发现

  • 试验共入组15459名儿童,至少1953名接受HIV检测,153名确认HIV感染(R3R组51名;R3C组54名;C3C组48名)。
  • 中位随访分别为39.3、39.4和38.3个月,R3R组92.2%(95%CI:81.1-97.8)、R3C组85.2%(95%CI:72.9-93.4)和C3C组87.5%(95%CI:74.8-95.3)报告SAEs。
  • 每组各有15名HIV感染参与者死亡(R3R组29.4%,R3C组27.8%,C3C组31.3%),无死亡被认为与疫苗接种相关。
  • 匹配病例对照分析中,第3剂后1个月抗CS几何平均抗体浓度在接种RTS,S/AS01的HIV感染儿童为193.3 EU/mL,在HIV状态未知或阴性的免疫原性对照为491.5 EU/mL(p=0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries. METHODS: Infants 6-12 weeks and children 5-17 months old were randomized to receive 4 RTS,S/AS01 doses (R3R group), 3 RTS,S/AS01 doses plus 1 comparator vaccine dose (R3C group), or 4 comparator vaccine doses (C3C group) at study months 0, 1, 2 and 20. Infants and children with WHO stage III/IV HIV disease were excluded but HIV testing was not routinely performed on all participants; our analyses included children identified as HIV-infected based on medical history or clinical suspicion and confirmed by polymerase chain reaction or antibody testing. Serious adverse events (SAEs) and anti-circumsporozoite (CS) antibodies were assessed. RESULTS: Of 15459 children enrolled in the trial, at least 1953 were tested for HIV and 153 were confirmed as HIV-infected (R3R: 51; R3C: 54; C3C: 48). Among these children, SAEs were reported for 92.2% (95% CI: 81.1-97.8) in the R3R, 85.2% (72.9-93.4) in the R3C and 87.5% (74.8-95.3) in the C3C group over a median follow-up of 39.3, 39.4 and 38.3 months, respectively. Fifteen HIV-infected participants in each group (R3R: 29.4%, R3C: 27.8%, C3C: 31.3%) died during the study. No deaths were considered vaccination-related. In a matched case-control analysis, 1 month post dose 3 anti-CS geometric mean antibody concentrations were 193.3 EU/mL in RTS,S/AS01-vaccinated HIV-infected children and 491.5 EU/mL in RTS,S/AS01-vaccinated immunogenicity controls with unknown or negative HIV status (p = 0.0001). CONCLUSIONS: The safety profile of RTS,S/AS01 in HIV-infected children was comparable to that of the comparator (meningococcal or rabies) vaccines. RTS,S/AS01 was immunogenic in HIV-infected children but antibody concentrations were lower than in children with an unknown or negative HIV status. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov: NCT00866619.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Otieno L, Guerra Mendoza Y, Adjei S, et al. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine. 2019. PMID: 31708182. doi:10.1016/j.vaccine.2019.10.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。